Clinical Trials Logo

Indolent B-cell Lymphomas clinical trials

View clinical trials related to Indolent B-cell Lymphomas.

Filter by:
  • None
  • Page 1

NCT ID: NCT03329950 Completed - Breast Cancer Clinical Trials

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Start date: December 1, 2017
Phase: Phase 1
Study type: Interventional

This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.

NCT ID: NCT02991638 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Start date: November 1, 2016
Phase: Phase 3
Study type: Interventional

Efficacy and Safety of ibrutinib in patients with chronic lymphocytic leukemia and other indolent B-cell lymphomas who are chronic hepatitis B virus carriers or occult hepatitis B virus carriers

NCT ID: NCT02904577 Active, not recruiting - Clinical trials for Indolent B-Cell Lymphomas

Indolent Non Follicular Lymphomas Prognostic Project

Start date: September 2011
Phase:
Study type: Observational

Prospective collection of data of possible prognostic relevance in patients with indolent non - follicular B-CELL Lymphomas.